Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The study aimed for:
1. Comparative evaluation of the safety of the drug Molnupiravir, capsules, 200 mg (JSC
"Valenta Pharm", Russia), and Lagevrio, capsules, 200 mg (Merck Sharp & Dohme (UK)
Limited, UK), based on the analysis of adverse events (AEs);
2. Comparative assessment of pharmacokinetic parameters and bioequivalence of the drug
Molnupiravir, capsules, 200 mg (Valenta Pharm JSC, Russia), and Lagevrio, capsules, 200
mg (Merck Sharp & Dohme (UK) Limited, UK), in healthy volunteers in fasted conditions.